[Federal Register Volume 84, Number 104 (Thursday, May 30, 2019)]
[Notices]
[Pages 25057-25059]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11220]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-19-19AWX; Docket No. CDC-2019-0042]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
Federal agencies the opportunity to comment on a proposed and/or 
continuing information collection, as required by the Paperwork 
Reduction Act of 1995. This notice invites comment on a proposed 
information collection project titled WISEWOMAN National Program 
Evaluation. The goal of the study is to assess the implementation of 
the WISEWOMAN program under the current cooperative agreement and 
measure the effect of the program on individual-, organizational-, and 
community-level outcomes.

DATES: CDC must receive written comments on or before July 29, 2019.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0042 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without change, all relevant comments 
to Regulations.gov.

    Please note:  Submit all comments through the Federal 
eRulemaking portal (regulations.gov) or by U.S. mail to the address 
listed above.


FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of

[[Page 25058]]

the information collection plan and instruments, contact Jeffrey M. 
Zirger, Information Collection Review Office, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 
30329; phone: 404-639-7570; Email: [email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
Federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected; and
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses.
    5. Assess information collection costs.

Proposed Project

    WISEWOMAN National Program Evaluation--New--National Center for 
Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for 
Disease Control and Prevention (CDC).

Background and Brief Description

    The CDC has supported the WISEWOMAN (Well-Integrated Screening and 
Evaluation for Women Across the Nation) program since 1995. The 
WISEWOMAN program is designed to serve low-income women ages 40-64 who 
have elevated risk factors for cardiovascular disease (CVD) and have no 
health insurance, or are underinsured for medical and preventive care 
services. Through the WISEWOMAN program, women have access to screening 
services for selected CVD risk factors such as elevated blood 
cholesterol, hypertension, and abnormal blood glucose levels; referrals 
to heathy behavior support programs; and referrals to medical care. 
WISEWOMAN participants must be co-enrolled in the CDC-sponsored 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
    The WISEWOMAN program is administered through cooperative 
agreements with state, territorial, or tribal health departments. Each 
WISEWOMAN recipient submits to CDC an annual progress report that 
describes program objectives and activities, and semi-annual data 
reports (known as minimum data elements, or MDE) on the screening, 
assessment, and healthy behavior support services offered to women who 
participate in the program. Participant-level MDE are de-identified 
prior to transmission to CDC.
    In 2018, CDC released the fifth funding opportunity announcement 
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal 
health departments, including 6 new and 18 continuing awardees from the 
previous NOFO. Key program elements were retained (e.g., provision of 
screening services, promotion of healthy lifestyle behaviors, and 
linkage to healthy behavior support services and community based 
resources), but a number of changes were incorporated into the program 
at that time. The current FOA reflects increased emphasis on three 
strategies to reduce CVD risk and support hypertension control and 
management, including: (1) Tracking and monitoring clinical measures, 
(2) implementing team-based care, and (3) linking community resources 
and clinical services to support care coordination, self-management, 
and lifestyle change.
    CDC seeks to conduct a one-time, multi-component evaluation to 
assess the effectiveness of the program on individual-, organizational-
, and community-level outcomes. The in-depth assessment is designed to 
complement the routine progress and MDE information already being 
collected from WISEWOMAN program recipients. The new data collection 
will focus on obtaining qualitative and quantitative information at the 
organizational and community levels about process and procedures 
implemented, and barriers, facilitators, and other contextual factors 
that affect program implementation and participant outcomes. Data 
collection activities will include a Program Survey with all WISEWOMAN 
awardee programs, administered in the second and fourth program years, 
and a one-time site visit to each recipient spread across the three-
year data collection effort. During site visits, semi-structured 
interviews will be conducted with WISEWOMAN staff members and staff at 
partner organizations, such as clinical providers and community-based 
resource providers, who are positioned to provide a variety of 
perspectives on program implementation.
    OMB approval is requested for three years. Participation is 
voluntary and there are no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient             Program survey..              18               1               1              16
 Administrators.
                                Site Visit                     8               1           90/60              12
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
Recipient partners............  Site Visit                    16               1               1              16
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.

[[Page 25059]]

 
Healthy behavior support staff  Site Visit                    16               1               1              16
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
Clinical providers............  Site Visit                    16               1               1              16
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............              84
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2019-11220 Filed 5-29-19; 8:45 am]
BILLING CODE 4163-18-P